Thalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients
✍ Scribed by Adriana Morgan Oliveira; Durvanei Augusto Maria; Martin Metzger; Camila Linardi; Ricardo Rodrigues Giorgi; Fernanda Moura; Gracia Aparecida Martinez; Sérgio Paulo Bydlowski; Estela Maria Novak
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 133 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
✦ Synopsis
The chemokine stromal-derived factor-1alpha (SDF-1alpha) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple myeloma. Here, we show that the expression of SDF-1alpha and CXCR4 was significantly down-regulated in patients treated with thalidomide (n=10) as compared to newly diagnosed MM patients (n=31) and MM patients treated with other drugs (n=38). SDF-1 alpha and CXCR4 expression was also significantly decreased in a RPMI 8226 cell line treated with 10 and 20micromol/L of thalidomide. Our findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1alpha in multiple myeloma.